RxDoctor Payments Data

Mandi Troli

Family · Momence, ILNPI 1346677895

Payments from drug & device makers

$7,407in general payments, 2019–2025

Across 402 payments — averaging $18.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Nestle Healthcare Nutrition Inc.$801
  • AstraZeneca$694
  • Boehringer Ingelheim$535
  • Lilly USA, LLC$493
  • Otsuka America Pharmaceutical, Inc.$376
  • plus $3K from 27 others

What the payments were for

  • Food & beverage$7,407100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,407 in reported general payments places this provider in the 95th percentile of 4,941 family providers in Illinois.

See all family providers in Illinois

Medicare billing

Part B allowed, 2024
$38,812
Medicare patients
109
Services billed
563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$21,437
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$17,456
Tiotropium Bromide11$4,310
SymbicortBudesonide/Formoterol Fumarate13$2,953
Montelukast Sodium107$1,762
Atorvastatin Calcium113$1,516
Gabapentin56$1,482
Albuterol Sulfate HfaAlbuterol Sulfate35$1,435
Levothyroxine Sodium85$1,416
Rosuvastatin Calcium94$1,189
Amlodipine Besylate89$830
Losartan Potassium77$766
Metoprolol Succinate33$665
Fluticasone Propionate38$631
Simvastatin40$617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$535$21,43714 claims
GSKTrelegy Ellipta$150$17,45628 claims
AstraZenecaSymbicort$694$2,95313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,941 family providers in Illinois.

Other family in Momence

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →